期刊
PSYCHIATRY RESEARCH
卷 239, 期 -, 页码 85-91出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2016.02.052
关键词
BDI-II; Biomarker; Depressive symptoms; HAMD-17; Immunity; Inflammation; Antidepressant treatment prediction
类别
To clarify findings of elevated cytokine levels in major depression (MD), this study aimed to investigate the relationship between serum levels of cytokines, symptoms of MD and antidepressant treatment outcome. At baseline (TO) and 4 weeks following initiation of antidepressant treatment (T1), levels of tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12, IL-13, granulocyte-macrophage-colony-stimulating-factor (GM-CSF), CRP and depression ratings HAMD-17 and BDI-II were assessed in 30 patients with MD and 30 age-and sex-matched controls. At TO, in the patient group, cytokines, but not CRP, negatively correlated with individual BDI-II-items, factors and seventies and showed both negative and positive correlations with HAMD-17 items. At T1 and within the controls, no such relationships were observed. At T0 and T1, levels of both pro- and anti-inflammatory cytokines were significantly higher in treatment responders (Delta HAMD-(17)T0-T1 >= 50%,n=15) compared to non-responders. When controlled for baseline BDI, differences between groups were only found significant for IL-2 at TO. The results suggest cytokines are not generally pro-depressive but rather relate to more specific regulation of symptoms and seventies in MD. Together with the association between cytokines and treatment responder status, these data support cytokines as a promising but still controversial biomarker of depression. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据